Huadong Medicine (000963.SZ): The clinical trial application for DR10624 injection medication has been approved by the US FDA.

Huadong Medicine (000963.SZ) announced that its holding subsidiary Zhejiang Daoer Biotechnology Co., Ltd. (referred to as "Daoer Biotechnology") has received a notification from the U.S. Food and Drug Administration (FDA) that the clinical trial application for the DR10624 injection submitted by Daoer Biotechnology has been approved by the FDA and can be conducted in the United States. The indication is severe hypertriglyceridemia (SHTG).